Use of a GLP-1R Agonist to Treat Opioid Use Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

September 13, 2023

Study Completion Date

September 13, 2023

Conditions

Opiate Substitution TreatmentOpioid-Related Disorders

Interventions

DRUG

Liraglutide Pen Injector

Liraglutide will be provided using an injection pen provided by the manufacturer

DRUG

Placebo

Placebo injection pen

Trial Locations (1)

Penn State Milton S Hershey Medical Center, Hershey

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Milton S. Hershey Medical Center

OTHER

NCT04199728 - Use of a GLP-1R Agonist to Treat Opioid Use Disorder | Biotech Hunter | Biotech Hunter